Analyst's ForecastAnalyst increases price target from $145 to $179 based on heightened confidence in Elevidys' label expansion, signaling a stronger investment outlook for Sarepta's stock.
Market ExpectationSurveyed investors' anticipation of label expansion for Elevidys in ambulant patients, with expected share price ranging from $130 to $200, reflects market optimism for the drug's approval and future sales.
Regulatory MilestoneThe FDA accelerating the review timeline for Elevidys to a four-month period underscores the agency's prioritization and enthusiasm for the drug's potential label expansion.